Department of Head and Neck Surgery, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan.
Department of Otorhinolaryngology, Shiga University of Medical Science, Otsu, Shiga, 520-2192, Japan.
Int J Clin Oncol. 2017 Dec;22(6):1034-1041. doi: 10.1007/s10147-017-1149-3. Epub 2017 Jun 16.
Laryngeal preservation is an important consideration when treating cervical esophageal cancers (CECs) such as laryngeal cancer. The standard treatment for CEC allowing laryngeal preservation is chemoradiotherapy. However, in cases of laryngeal cancer, chemoselection has also been applied as a treatment strategy that promotes larynx preservation. This strategy involves assigning the appropriate radical treatment according to the primary tumor's response to induction chemotherapy. Since there have been no studies of the application of chemoselection in CEC cases, the present study compared the results, including laryngeal preservation rates, obtained upon applying chemoselection and chemoradiotherapy to CEC.
This was a retrospective cohort study of cervical esophageal squamous cell carcinoma patients treated using chemoselection or chemoradiotherapy at Aichi Cancer Center Hospital between January 2000 and March 2013. A total of 42 patients were enrolled.
The 2-year overall survival and laryngeal preservation rates for the chemoselection group versus the primary radiotherapy group were 65.1 and 57.3 versus 40 and 83.3%, respectively (P = 0.017 and P = 0.122, respectively). The 2-year locoregional control rates for the chemoselection and primary radiotherapy groups were 68 and 25%, respectively (P = 0.045).
The chemoselection group achieved favorable results. Therefore, chemoselection can be applied as a treatment strategy for CEC.
在治疗喉癌等颈段食管癌（CEC）时，需要考虑保留喉部。允许保留喉部的 CEC 的标准治疗方法是放化疗。然而，在喉癌的情况下，化疗选择也被应用为一种促进保留喉部的治疗策略。该策略涉及根据原发肿瘤对诱导化疗的反应来分配适当的根治性治疗。由于目前尚无关于在 CEC 病例中应用化疗选择的研究，本研究比较了在 Aichi Cancer Center Hospital 于 2000 年 1 月至 2013 年 3 月期间应用化疗选择和放化疗治疗 CEC 时获得的结果，包括保留喉部的比率。
这是一项回顾性队列研究，纳入了在 Aichi Cancer Center Hospital 接受化疗选择或放化疗治疗的颈段食管鳞状细胞癌患者。共纳入 42 例患者。
化疗选择组与原发放疗组的 2 年总生存率和保留喉部率分别为 65.1%和 57.3%比 40%和 83.3%（P=0.017 和 P=0.122）。化疗选择组和原发放疗组的 2 年局部区域控制率分别为 68%和 25%（P=0.045）。
化疗选择组取得了良好的结果。因此，化疗选择可以作为 CEC 的治疗策略。
